Dr Mohsen Shafiei is an experienced medical oncologist who is dedicated to improving the lives of people living with advanced cancer. His supportive, gentle manner and ability to explain complex information in plain language ensures his patients feel well-informed and empowered throughout treatment and beyond.
Biography
Dr Mohsen Shafiei is an experienced medical oncologist at Icon Cancer Centre Revesby. Dr Shafiei completed a Doctor of Medicine (MD) from the University of Rafsanjan, Iran in 2003. He moved to Sydney in 2006, where he completed his general medical training through the Central Coast and South Western Sydney Local Health Districts.
Dr Shafiei undertook Advanced Training in Clinical Genetics in Sydney and received specialist medical oncology training at the Calvary Mater Newcastle. He became a Fellow of the Royal Australasian College of Physicians in 2016.
Dr Shafiei has a strong passion for improving the quality of care and treatments available for patients through knowledge gained from clinical research, trials and medical education. Driven by this, he pursued a dual clinical-researcher pathway and completed a PhD focused on individualised dosing of anti-cancer therapy for older patients at the University of Sydney in 2023.
He has been the Director of Physician Education at Bankstown Hospital since 2019, and regularly holds general medicine and oncology lectures for medical students and junior doctors. He also maintains an active role in the South Western Sydney and Western New South Wales multidisciplinary team (MDT) meetings for lung, breast, head and neck, genitourinary, skin cancers and melanoma.
Alongside his practice at Icon, Dr Shafiei is a medical oncologist at Bankstown Hospital and Western Cancer Centre Dubbo. He speaks fluent Persian and English and looks forward to supporting patients in a language they are familiar with.
His clinical experience covers a wide range of solid tumour malignancies, with a special interest in lung cancer, mesothelioma, melanoma and skin cancers, gastrointestinal cancer, head and neck cancer, and breast cancer.